The role of nuclear factor of activated T cells in pulmonary arterial hypertension

References

• Shou J, Jing J, Xie J, You L, Jing Z, Yao J, Han W, Pan H. Nuclear factor of activated T cells in cancer development and treatment. Cancer Lett 2015; 361(2):174-184; PMID:25766658; http://dx.doi.org/10.1016/j.canlet.2015.03.005
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S):5S-12S; http://dx.doi.org/10.1016/j.jacc.2004.02.037
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Tuder RM, El Kasmi KC. Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxicpulmonary hypertension. J Appl Physiol (1985) 2015; 119(10):1164-1172; PMID:25930027; http://dx.doi.org/10.1152/japplphysiol.00283.2015
   PubMed Web of Science ®Google Scholar
• El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012; 55(2):218-228; http://dx.doi.org/10.1016/j.pcad.2012.07.006
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54(1 Suppl):S10-S19; http://dx.doi.org/10.1016/j.jacc.2009.04.006
   PubMedGoogle Scholar
• Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science. 1988; 241(4862):202-205; PMID:3260404; http://dx.doi.org/10.1126/science.3260404
   PubMed Web of Science ®Google Scholar
• Nilsson LM, Nilsson-Ohman J, Zetterqvist AV, Gomez MF. Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys? Curr Opin Lipidol 2008; 19(5):483-490
   PubMed Web of Science ®Google Scholar
• Lorgen M, Jorgensen EH, Jordan WC, Martin SA, Hazlerigg DG. NFAT5 genes are part of the osmotic regulatory system in Atlantic salmon (Salmo salar). Mar Genomics 2016; pii: S1874-7787(16)30058-7
   Google Scholar
• Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2009; 9(11):810-820; PMID:19851316; http://dx.doi.org/10.1038/nrc2735
   PubMed Web of Science ®Google Scholar
• Pan MG, Xiong Y, Chen F. NFAT gene family in inflammation and cancer. Curr Mol Med 2013; 13(4):543-554; PMID:22950383; http://dx.doi.org/10.2174/1566524011313040007
   PubMed Web of Science ®Google Scholar
• Chen L, Glover JN, Hogan PG, Rao A, Harrison SC. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature. 1998; 392(6671):42-48; PMID:9510247; http://dx.doi.org/10.1038/32100
   PubMed Web of Science ®Google Scholar
• Medyouf H, Ghysdael J. The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008; 7(3):297-303.
   PubMed Web of Science ®Google Scholar
• Fric J, Zelante T, Wong AY, Mertes A, Yu HB, Ricciardi-Castagnoli P. NFAT control of innate immunity. Blood 2012; 120(7):1380-1389; PMID:22611159; http://dx.doi.org/10.1182/blood-2012-02-404475
   PubMed Web of Science ®Google Scholar
• Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007;104(27):11418-23.
   Google Scholar
• Guignabert C, Tu L, Izikki M, Dewachter L, Zadigue P, Humbert M, Adnot S, Fadel E, Eddahibi S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J 2009; 23(12):4135-4147; PMID:19679640; http://dx.doi.org/10.1096/fj.09-131664
   PubMed Web of Science ®Google Scholar
• Li M, Liu Y, Sun X, Li Z, Liu Y, Fang P, He P, Shi H, Xie M, Wang X, et al. Sildenafil inhibits calcineurin/NFATc2-mediated cyclin A expression in pulmonary artery smooth muscle cells. Life Sci 2011; 89(17–18):644-649.
   PubMed Web of Science ®Google Scholar
• Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011; 123(11):1205-1215.
   PubMed Web of Science ®Google Scholar
• Zimmer J, Takahashi T, Hofmann AD, Puri P. Imbalance of NFATc2 and KV1.5 Expression in Rat Pulmonary Vasculature of Nitrofen-Induced Congenital Diaphragmatic Hernia. Eur J Pediatr Surg. 2017;27(1):68–73. doi: 10.1055/s-0036-1587589.
   Google Scholar
• Moudgil R, Michelakis ED, Archer SL. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation 2006; 13(8):615-632; PMID:17085423; http://dx.doi.org/10.1080/10739680600930222
   PubMed Web of Science ®Google Scholar
• Gross A. BCL-2 family proteins as regulators of mitochondria metabolism. Biochim Biophys Acta 2016; 1857(8):1243-1246; http://dx.doi.org/10.1016/j.bbabio.2016.01.017
   PubMed Web of Science ®Google Scholar
• Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAKSTAT 2012; 1(4):223-233; PMID:24058777
   PubMedGoogle Scholar
• Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension. Circ Res 2013; 113(2):126-136.
   PubMed Web of Science ®Google Scholar
• Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC, et al. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med 2011; 3:88ra55; PMID:21697531; http://dx.doi.org/10.1126/scitranslmed.3002194
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang J, Yi B, Chen M, Qi J, Yin Y, Lu X, Jasmin JF, Sun J. Nur77 suppresses pulmonary artery smooth muscle cell proliferation through inhibition of the STAT3/Pim-1/NFAT pathway. Am J Respir Cell Mol Biol 2014; 50(2):379-388; PMID:24047441
   PubMed Web of Science ®Google Scholar
• Assad TR, Hemnes AR. Metabolic Dysfunction in Pulmonary Arterial Hypertension. Curr Hypertens Rep 2015; 17(3):20; PMID:25754317; http://dx.doi.org/10.1007/s11906-014-0524-y
   PubMed Web of Science ®Google Scholar
• Sutendra G, Dromparis P, Bonnet S, Haromy A, McMurtry MS, Bleackley RC, Michelakis ED. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011; 89(8):771-783; PMID:21809123; http://dx.doi.org/10.1007/s00109-011-0762-2
   PubMed Web of Science ®Google Scholar
• Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2010; 2(44):44ra58; PMID:20702857; http://dx.doi.org/10.1126/scitranslmed.3001327
   PubMed Web of Science ®Google Scholar
• Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S, Provencher S. Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ 2013; 3(1):74-81; PMID:23662177; http://dx.doi.org/10.4103/2045-8932.109917
   PubMedGoogle Scholar
• Bierer R, Nitta CH, Friedman J, Codianni S, de Frutos S, Dominguez-Bautista JA, Howard TA, Resta TC, Bosc LV. NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adultand neonatal mice. Am J Physiol Lung Cell Mol Physiol 2011; 301(6):L872-880; PMID:21908592; http://dx.doi.org/10.1152/ajplung.00405.2010
   PubMedGoogle Scholar
• Walther S, Awad S, Lonchyna VA, Blatter LA. NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure. Am J Physiol Heart Circ Physiol 2014; 306(6):H856-866; PMID:24441548; http://dx.doi.org/10.1152/ajpheart.00353.2013
   PubMedGoogle Scholar
• Wang C, Li JF, Zhao L, Liu J, Wan J, Wang YX, Wang J, Wang C. Inhibition of SOC/Ca2+/NFAT pathway is involved in the antiproliferative effect of sildenafil on pulmonaryartery smooth muscle cells. Respir Res 2009; 10:123; PMID:20003325; http://dx.doi.org/10.1186/1465-9921-10-123
   PubMed Web of Science ®Google Scholar
• Hou X, Chen J, Luo Y, Liu F, Xu G, Gao Y. Silencing of STIM1 attenuates hypoxia-induced PASMCs proliferation via inhibition of the SOC/Ca2+/NFAT pathway. Respir Res 2013; 14:2; PMID:23289723; http://dx.doi.org/10.1186/1465-9921-14-2
   PubMed Web of Science ®Google Scholar
• Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, Huertas A, Humbert M, Montani D. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev 2013; 22(130):543-551; PMID:24293470; http://dx.doi.org/10.1183/09059180.00007513
   PubMedGoogle Scholar
• Amberg GC, Rossow CF, Navedo MF, Santana LF. NFATc3 regulates Kv2.1 expression in arterial smooth muscle. J Biol Chem 2004; 279(45):47326-47334; PMID:15322114; http://dx.doi.org/10.1074/jbc.M408789200
   PubMed Web of Science ®Google Scholar
• de Frutos S, Diaz JM, Nitta CH, Sherpa ML, Bosc LV. Endothelin-1 contributes to increased NFATc3 activation by chronic hypoxia in pulmonary arteries. Am J Physiol Cell Physiol 2011; 301(2):C441-450; PMID:21525433; http://dx.doi.org/10.1152/ajpcell.00029.2011
   PubMedGoogle Scholar
• de Frutos S, Nitta CH, Caldwell E, Friedman J, González Bosc LV. Regulation of soluble guanylyl cyclase- alpha 1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR. Am J Physiol Lung Cell Mol Physiol 2009; 297(3):L475-486; PMID:19592461; http://dx.doi.org/10.1152/ajplung.00060.2009
   PubMedGoogle Scholar
• de Frutos S, Spangler R, Alò D, Bosc LV. NFATc3 mediates chronic hypoxi-induced pulmonary arterial remodeling with alpha-actin up-regulation. J Biol Chem 2007; 282(20):15081-15089; PMID:17403661; http://dx.doi.org/10.1074/jbc.M702679200
   PubMed Web of Science ®Google Scholar
• Kang K, Peng X, Zhang X, Wang Y, Zhang L, Gao L, Weng T, Zhang H, Ramchandran R, Raj JU, et al. MicroRNA 124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genesand inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem 2013; 288(35):25414-25427; PMID:23853098; http://dx.doi.org/10.1074/jbc.M113.460287
   PubMed Web of Science ®Google Scholar
• Said SI. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann N Y Acad Sci 2008; 1144:148-153.
   PubMed Web of Science ®Google Scholar
• Ramiro-Diaz JM, Nitta CH, Maston LD, Codianni S, Giermakowska W, Resta TC, Gonzalez Bosc LV. NFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice. Am J Physiol Lung Cell Mol Physiol 2013; 304(9):L613-625; PMID:23475768; http://dx.doi.org/10.1152/ajplung.00408.2012
   PubMedGoogle Scholar
• Singh NK, Kundumani-Sridharan V, Kumar S, Verma SK, Kotla S, Mukai H, Heckle MR, Rao GN. Protein kinase N1 is a novel substrate of NFATc1-mediated cyclin D1-CDK6 activity and modulates vascular smooth muscle cell division and migration leading to inward blood vessel wall remodeling. J Biol Chem 2012; 287(43):36291-36304; PMID:22893700; http://dx.doi.org/10.1074/jbc.M112.361220
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang C, Dronadula N, Li Q, Rao GN. Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model. J Biol Chem 2005; 280(15):14700-14708; PMID:15681847; http://dx.doi.org/10.1074/jbc.M500322200
   PubMed Web of Science ®Google Scholar
• Boss V, Abbott KL, Wang XF, Pavlath GK, Murphy TJ. The cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) proteins are expressed in vascular smooth muscle cells. Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase C-coupled cell surface receptors. J Biol Chem 1998; 273(31):19664-19671.
   PubMed Web of Science ®Google Scholar
• Larrieu D, Thiébaud P, Duplàa C, Sibon I, Thézé N, Lamazière JM. Activation of the Ca(2+)/calcineurin/NFAT2 pathway controls smooth muscle cell differentiation. Exp Cell Res 2005; 310(1):166-175; PMID:16129432; http://dx.doi.org/10.1016/j.yexcr.2005.07.021
   PubMed Web of Science ®Google Scholar
• Rosenkranz AC, Rauch BH, Doller A, Eberhardt W, Böhm A, Bretschneider E, Schrör K. Regulation of human vascular protease-activated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T cells (NFAT). Mol Pharmacol 2011; 80(2):337-344.
   PubMed Web of Science ®Google Scholar
• Yellaturu CR, Ghosh SK, Rao RK, Jennings LK, Hassid A, Rao GN. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupledreceptor agonist-induced cell proliferation. Biochem J 2002; 368(Pt 1):183-190; PMID:12188924; http://dx.doi.org/10.1042/bj20020347
   PubMed Web of Science ®Google Scholar
• Chan MC, Weisman AS, Kang H, Nguyen PH, Hickman T, Mecker SV, Hill NS, Lagna G, Hata A. The amiloride derivative phenamil attenuates pulmonary vascular remodeling by activating NFAT and the bone morphogenetic protein signaling pathway. Mol Cell Biol 2011; 31(3):517-530; PMID:21135135; http://dx.doi.org/10.1128/MCB.00884-10
   PubMed Web of Science ®Google Scholar
• Sadamura-Takenaka Y, Ito T, Noma S, Oyama Y, Yamada S, Kawahara K, Inoue H, Maruyama I. HMGB1 promotes the development of pulmonary arterial hypertension in rats. PLoS One 2014; 9(7):e102482; PMID:25032709; http://dx.doi.org/10.1371/journal.pone.0102482
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang L, Hu J, Liu H. Role of nuclear factor of activated T cells-2 in high mobility protein box-1 release in human monocytic THP-1 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2016; 36(1):8-12; PMID:26806731
   PubMedGoogle Scholar
• Parpaite T, Cardouat G, Mauroux M, Gillibert-Duplantier J, Robillard P, Quignard JF, Marthan R, Savineau JP, Ducret T. Effect of hypoxia on TRPV1 and TRPV4 channels in rat pulmonary arterial smooth muscle cells. Pflugers Arch 2016; 468(1):111-130; PMID:25799977; http://dx.doi.org/10.1007/s00424-015-1704-6
   PubMed Web of Science ®Google Scholar
• Morelli S, Giordano M, De Marzio P, Priori R, Sgreccia A, Valesini G. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus. 1993; 2(6):367-369; PMID:8136819; http://dx.doi.org/10.1177/096120339300200606
   PubMed Web of Science ®Google Scholar
• Padeh S, Laxer RM, Silver MM, Silverman ED. Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum. 1991; 34(12):1575-1579; PMID:1747143; http://dx.doi.org/10.1002/art.1780341216
   PubMed Web of Science ®Google Scholar
• Kockx M, Jessup W, Kritharides L. Cyclosporin A and atherosclerosis–cellular pathways in atherogenesis. Pharmacol Ther 2010; 128(1):106-118. doi: 10.1016/j.pharmthera.2010.06.001
   PubMed Web of Science ®Google Scholar
• Yu H, van Berkel TJ, Biessen EA. Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, incardiovascular disorders. Cardiovasc Drug Rev 2007; 25(2):175-187; PMID:17614939; http://dx.doi.org/10.1111/j.1527-3466.2007.00011.x
   PubMed Web of Science ®Google Scholar
• McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005; 115(3):538-546; PMID:15765135; http://dx.doi.org/10.1172/JCI24144
   PubMed Web of Science ®Google Scholar
• Bîrsan T, Dambrin C, Marsh KC, Jacobsen W, Djuric SW, Mollison KW, Christians U, Carter GW, Morris RE. Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT. Transpl Int 2004; 17(3):145-150; PMID:14735234; http://dx.doi.org/10.1111/j.1432-2277.2004.tb00419.x
   PubMed Web of Science ®Google Scholar
• Trevillyan JM, Chiou XG, Chen YW, Ballaron SJ, Sheets MP, Smith ML, Wiedeman PE, Warrior U, Wilkins J, Gubbins EJ, et al. Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. J Biol Chem 2001; 276(51):48118-48126; PMID:11592964
   PubMed Web of Science ®Google Scholar
• Nilsson-Berglund LM, Zetterqvist AV, Nilsson-Ohman J, Sigvardsson M, Gonzalez Bosc LV, Smith ML, Salehi A, Agardh E, Fredrikson GN, Agardh CD, et al. Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia. Arterioscler Thromb Vasc Biol 2010; 30(2):218-224; http://dx.doi.org/10.1161/ATVBAHA.109.199299
   PubMed Web of Science ®Google Scholar
• Kishimoto Y, Kato T, Ito M, Azuma Y, Fukasawa Y, Ohno K, Kojima S. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects. J Thorac Cardiovasc Surg 2015; 150(3):645-654; http://dx.doi.org/10.1016/j.jtcvs.2015.05.052
   PubMed Web of Science ®Google Scholar
• Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, et al. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J 2012; 40(3):618-629; PMID:22496325; http://dx.doi.org/10.1183/09031936.00084211
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12):896-903; PMID:11907289; http://dx.doi.org/10.1056/NEJMoa012212
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358(9288):1119-1123; PMID:11597664; http://dx.doi.org/10.1016/S0140-6736(01)06250-X
   PubMed Web of Science ®Google Scholar
• Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber C, Macdonald PS. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102(4):411-418; http://dx.doi.org/10.1161/01.CIR.102.4.411
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N, STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47(10):2049-2056; PMID:16697324; http://dx.doi.org/10.1016/j.jacc.2006.01.057
   PubMed Web of Science ®Google Scholar
• Kawamura T, Ono K, Morimoto T, Akao M, Iwai-Kanai E, Wada H, Sowa N, Kita T, Hasegawa K. Endothelin-1-dependent nuclear factor of activated T lymphocyte signaling associates with transcriptional coactivator p300 in the activation of the B cell leukemia-2 promoter in cardiac myocytes. Circ Res 2004; 94(11):1492-1499.
   PubMed Web of Science ®Google Scholar
• Liu J, Han Z, Han Z, He Z. Mesenchymal stem cell-conditioned media suppresses inflammation-associated overproliferation of pulmonary artery smooth muscle cells in a rat model of pulmonary hypertension. Exp Ther Med 2016; 11(2):467-475; PMID:26893632
   PubMed Web of Science ®Google Scholar
• Liu J, Han Z, Han Z, He Z. Mesenchymal stem cells suppress CaN/NFAT expression in the pulmonary arteries of rats with pulmonary hypertension. Exp Ther Med 2015; 10(5):1657-166; PMID:26640533
   PubMed Web of Science ®Google Scholar